Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

3SBio Pays $100 Million to Market Two AstraZeneca Diabetes Drugs in China

publication date: Oct 11, 2016
3SBio paid $100 million for exclusive rights to market two AstraZeneca diabetes products in China. The two products, Byetta and Bydureon, are injectable Glucagon-Like Peptide-1 antagonists intended for type 2 diabetes patients. Byetta is dosed twice-daily while Bydureon is administered once per week. 3SBio will pay $50 million upfront and $25 million when China issues import licenses for the Bydureon single dose tray and again for the Bydureon dual chamber pen. Previously, 3SBio was not involved in the diabetes market. More details....

Stock Symbols: (HK: 01530) (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here